Format

Send to

Choose Destination
Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.

Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response.

Author information

1
Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.
2
Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.

Abstract

There are limited real-world data on the efficacy of direct acting antiviral (DAA) therapy for hepatitis C (HCV) in Australia. In this study, the efficacy of DAA therapy for HCV was compared between cirrhotic and non-cirrhotic cohorts. Patients without end-of-treatment response (EoTR) were observed to ascertain likelihood of achieving sustained virological response at 12 weeks post-treatment (SVR12). A total of 334 patients with HCV was included. Overall SVR12 was 96.7% with minimal differences in SVR12 between the cirrhosis and non-cirrhosis groups (95.7 and 97.3%). There were 20 patients (5.99%) that failed to achieve an EoTR of which 80.0% (n = 16) went on to achieve SVR12. These results suggest DAA therapy is effective with high rates of SVR12 even in patients that do not achieve an EoTR.

KEYWORDS:

cirrhosis; daclatasvir; hepatitis C; ledipasvir; sofosbuvir

PMID:
31083802
DOI:
10.1111/imj.14279

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center